Form 4: Sarepta Therapeutics Director Deirdre P. Connelly Reports Stock and Option Awards

Director Deirdre P. Connelly reports the acquisition of restricted stock units and stock options in Sarepta Therapeutics.

Summary

• Deirdre P. Connelly, a director of Sarepta Therapeutics, reported the acquisition of 2,842 shares of common stock in the form of restricted stock units (RSUs) and an option to purchase 6,442 shares of common stock.
• The RSUs were granted on September 12, 2024, and vest in three equal annual installments beginning September 12, 2025.
• The stock options have an exercise price of $125.34, were granted on September 12, 2024, and also vest in three equal annual installments beginning September 12, 2025, expiring on September 12, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard executive compensation practices, aligning director interests with shareholders. There are no indications of negative events or concerns.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The grant of equity-based compensation can incentivize the director to work towards increasing shareholder value.

Key Dates